HIV and Hepatitis.com Coverage of the
45th Interscience Conference on Antimicrobial Agents
and Chemotherapy
 December 16 - 19, 2005, Washington, DC
Library of Posters
Entry Inhibitors
Protease Inhibitors and Ritonavir-boosted PIs
Non Nucleoside Reverse Transcriptase Inhibitors
Nucleoside/Nucleotide Reverse Transcriptase Inhibitors
Therapy for Treatment-naive Patients
Therapy for Treatment-experienced Patients
Adherence
Pharmacokinetic (PK) and Drug-drug Interactions
Drug Resistance
Dosing and New Formulations
Lipodystrophy
Renal Safety
Switch Studies

Entry Inhibitors       TOP
Towards Gene Knock Out Therapy for AIDS/HIV: Targeted Disruption of CCR5 Using Engineered Zinc Finger Protein Nucleases (ZFNs). Y Jouvenot and others.

The Pharmacokinetic Interaction Between the Entry Inhibitor Aplaviroc (APL, 873140) and Efavirenz in Healthy Adults. K Adkinson and others.

Absence of Pharmacokinetic (PK) Drug Interaction Between Aplaviroc (APL, 873140) and Tenofovir Disoproxil Fumarate (TDF). I Song and others.

Analysis of In Vitro-Derived Viruses Exhibiting Reduced Susceptibility to Aplaviroc. C Labranche and others.

Co-administration of Fosamprenavir/Ritonavir Overcomes the Effect of Efavirenz Induction on Aplaviroc (APL; 873140) Pharmacokinetics. K Adkinson and others.

Minimal to No Changes in Plasma Chemokine/Cytokine Levels in HIV-Negative and HIV-Positive Subjects Following Short Term Administration of Aplaviroc K Kitrinos and others.
Protease Inhibitors and Ritonavir-boosted PIs       TOP
Co-administration of Fosamprenavir/Ritonavir Overcomes the Effect of Efavirenz Induction on Aplaviroc (APL; 873140) Pharmacokinetics, K Adkinson and others.

Pharmacokinetic Interaction Between Rifabutin (RFB) and Fosamprenavir (FPV)/ Ritonavir (RTV) in Healthy Subjects, Y Chon and others.

First Report of Development of Resistance to Boosted Fosamprenavir in an ART-naïve Subject: Virologic and Clinical Outcome. P Sax and others.

New Tablet Formulation of Lopinavir/Ritonavir Is Bioequivalent to the Capsule at a Dose of 800/200 mg. T Zhu and others.

Comparative Safety and Anti-HIV Activity of a Dual Protease Inhibitor Regimen (Lopinavir/ritonavir + Saquinavir) versus a Nucleoside-Containing Regimen. D Cameron and others.
Non Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)    TOP
The Pharmacokinetic Interaction Between the Entry Inhibitor Aplaviroc (APL, 873140) and Efavirenz in Healthy Adults. K Adkinson and others.

Co-administration of Fosamprenavir/Ritonavir Overcomes the Effect of Efavirenz Induction on Aplaviroc (APL; 873140) Pharmacokinetics. K Adkinson and others.

Regimens Containing Abacavir (ABC), Lamivudine (3TC), Zidovudine (ZDV), and Efavirenz (EFV) Do Not Affect GFR During Long-Term Treatment of HIV Naïve Subjects. D Sutherland-Phillips and others.
Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs)  TOP
Effects of Switching from Fixed Dose Zidovudine/Lamivudine (CBV) to Fixed Dose Tenofovir DF/Emtricitabine (TVD): Maintenance of Virologic Suppression and Other Benefits. E DeJesus and others.

Effect of Tenofovir in Combination with Other Anti-HIV NRTIs on Intracellular Nucleotide Pools. J Vela and others.

Lipid Changes in a Randomised, 48-week, Open Label Comparative Study of Tenofovir DF vs. Abacavir as Substitutes for a Thymidine Analog in Persons with Lipoatrophy: The RAVE Study. G Moyle and others.

Long-Term Virologic Follow-up of Patients Taking Tenofovir DF with Low-Level HIV-1 Viremia and the K65R Mutation In HIV-1 RT. B Chappell and others.

Similar Renal Safety Profile Between Tenofovir DF (TDF) and Stavudine (d4T) Using Modification of Diet in Renal Disease (MDRD) and Cockroft-Gault (CG) Estimation of Glomerular Filtration Rate (GFR) in Antiretroviral-Naïve Patients Through 144 Weeks. J Gallant and others.

Absence of Pharmacokinetic (PK) Drug Interaction Between Aplaviroc (APL, 873140) and Tenofovir Disoproxil Fumarate (TDF). I Song and others.

Selection of HIV Reverse Transcriptase (RT) Thymidine Analogue Mutations (TAMS) Rather than K65R is the Preferred Route of Resistance Seen in Patients with Virologic Failure on Once-Daily (QD) Trizivir (TZV) and Tenofovir (TDF). R Elion and others.

Selection for S68G/N/D Mutations of HIV-1 Reverse Transcriptase (RT) in Antiretroviral-Naïve Subjects Treated with Tenofovir (TDF)/Abacavir (ABC)/Lamivudine (3TC) Therapy. L Ross and others.

Population and Clonal Sequence Analyses In HIV-1+ Subjects Treated With Abacavir (ABC)/Lamivudine (3TC)/Efavirenz (EFV). A Moffitt and others.

Week 48 Analysis of Once-Daily (QD) Trizivir (TZV) and Tenofovir DF (TDF) in Antiretroviral Naïve Subjects (COL40263). C Cohen and others.

Regimens Containing Abacavir (ABC), Lamivudine (3TC), Zidovudine (ZDV), and Efavirenz (EFV) Do Not Affect GFR During Long-Term Treatment of HIV Naïve Subjects. D Sutherland-Phillips and others.
Therapy for Treatment-naive Patients       TOP
TMC114/r in 3-class-experienced patients: 24-week primary safety analysis of the POWER 2 study (TMC114-C202). D Berger and others.

Rising Multiple-Dose Assessment of Vicriviroc – Similar Safety, Tolerability, and Pharmacokinetics in Uninfected and HIV-Infected Adults. A Sansone and others.

First Report of Development of Resistance to Boosted Fosamprenavir in an ART-naïve Subject: Virologic and Clinical Outcome. P Sax and others.

Regimens Containing Abacavir (ABC), Lamivudine (3TC), Zidovudine (ZDV), and Efavirenz (EFV) Do Not Affect GFR During Long-Term Treatment of HIV Naïve Subjects. D Sutherland-Phillips and others.

Selection for S68G/N/D Mutations of HIV-1 Reverse Transcriptase (RT) in Antiretroviral-Naïve Subjects Treated with Tenofovir (TDF)/Abacavir (ABC)/Lamivudine (3TC) Therapy. L Ross and others.

Week 48 Analysis of Once-Daily (QD) Trizivir (TZV) and Tenofovir DF (TDF) in Antiretroviral Naïve Subjects (COL40263). C Cohen and others.
Therapy for Treatment-experienced       TOP
Rising Multiple-Dose Assessment of Vicriviroc – Similar Safety, Tolerability, and Pharmacokinetics in Uninfected and HIV-Infected Adults. A Sansone and others.
Adherence       TOP
Differences in Treatment Compliance Between Lopinavir/ritonavir (LPV/r) Given Once (QD) Versus Twice (BID) Daily Do Not Affect Virologic or Immunologic Outcomes. R Rode and others.
Pharmacokinetic (PK) and Drug-drug Interactions       TOP
The Pharmacokinetic Interaction Between the Entry Inhibitor Aplaviroc (APL, 873140) and Efavirenz in Healthy Adults. K Adkinson and others.

Rising Multiple-Dose Assessment of Vicriviroc – Similar Safety, Tolerability, and Pharmacokinetics in Uninfected and HIV-Infected Adults. A Sansone and others.

Absence of Pharmacokinetic (PK) Drug Interaction Between Aplaviroc (APL, 873140) and Tenofovir Disoproxil Fumarate (TDF). I Song and others.

Co-administration of Fosamprenavir/Ritonavir Overcomes the Effect of Efavirenz Induction on Aplaviroc (APL; 873140) Pharmacokinetics, K Adkinson and others.

Pharmacokinetic Interaction Between Rifabutin (RFB) and Fosamprenavir (FPV)/ Ritonavir (RTV) in Healthy Subjects, Y Chon and others.
Drug Resistance       TOP
Long-Term Virologic Follow-up of Patients Taking Tenofovir DF with Low-Level HIV-1 Viremia and the K65R Mutation In HIV-1 RT. B Chappell and others.

First Report of Development of Resistance to Boosted Fosamprenavir in an ART-naïve Subject: Virologic and Clinical Outcome. P Sax and others.

HIV-1 RT Mutations K70E and K65R are Not Present on the Same Viral Genome when Both Mutations are Detected in Plasma. R Lloyd and others.

Selection for S68G/N/D Mutations of HIV-1 Reverse Transcriptase (RT) in Antiretroviral-Naïve Subjects Treated with Tenofovir (TDF)/Abacavir (ABC)/Lamivudine (3TC) Therapy. L Ross and others.

Selection of HIV Reverse Transcriptase (RT) Thymidine Analogue Mutations (TAMS) Rather than K65R is the Preferred Route of Resistance Seen in Patients with Virologic Failure on Once-Daily (QD) Trizivir (TZV) and Tenofovir (TDF). R Elion and others.
Dosing and New Formulations       TOP
First Report of Development of Resistance to Boosted Fosamprenavir in an ART-naïve Subject: Virologic and Clinical Outcome. P Sax and others.

Week 48 Analysis of Once-Daily (QD) Trizivir (TZV) and Tenofovir DF (TDF) in Antiretroviral Naïve Subjects (COL40263). C Cohen and others.

Differences in Treatment Compliance Between Lopinavir/ritonavir (LPV/r) Given Once (QD) Versus Twice (BID) Daily Do Not Affect Virologic or Immunologic Outcomes. R Rode and others.
Switch Studies       TOP
Effects of Switching from Fixed Dose Zidovudine/Lamivudine (CBV) to Fixed Dose Tenofovir DF/Emtricitabine (TVD): Maintenance of Virologic Suppression and Other Benefits. E DeJesus and others.
Renal Safety       TOP
Similar Renal Safety Profile Between Tenofovir DF (TDF) and Stavudine (d4T) Using Modification of Diet in Renal Disease (MDRD) and Cockroft-Gault (CG) Estimation of Glomerular Filtration Rate (GFR) in Antiretroviral-Naïve Patients Through 144 Weeks. J Gallant and others.
Lipodystrophy       TOP
Lipid Changes in a Randomised, 48-week, Open Label Comparative Study of Tenofovir DF vs. Abacavir as Substitutes for a Thymidine Analog in Persons with Lipoatrophy: The RAVE Study. G Moyle and others.
























































Conference
Coverage
Main Page

Library of Posters

HOME
HIV and AIDS
  Main Page



JUMP TO
A SECTION